[{"id":"a50db79e-f985-4b65-9c1b-fc575cc8904a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04715191","created_at":"2021-01-21T06:52:06.961Z","updated_at":"2024-07-02T16:35:05.923Z","phase":"Phase 1","brief_title":"Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors","source_id_and_acronym":"NCT04715191","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GLYCAR T cells • GPC3-CAR and IL15 plus IL21 • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/03/2024","start_date":" 07/03/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 07/03/2041","study_completion_date":" 07/03/2041","last_update_posted":"2024-05-06"}]